A wave of excitement over using marijuana medically to alleviate symptoms associated with a variety of disease had GW Pharmaceuticals (GWPH) rewarding investors with significant returns in 2014. However, recent stumbles in the company's pipeline have weighed on shares lately.
In the wake of news last month showing that its marijuana drug cannibidiol for the treatment of schizophrenia posted mixed results, investors knocked shares down by 14%. In the following slideshow, I offer up insight into GW Pharmaceuticals' hopes for marijuana medicine and what investors will be watching closely over the coming months.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here.
